Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab - Archive ouverte HAL Access content directly
Journal Articles Pharmacogenomics Year : 2015

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

(1, 2) , (1, 2) , (1, 2) , (3) , (1) , (3) , (1, 2) , (1, 2) , (3) , (1, 2) , (1, 2)
1
2
3

Abstract

Aim: The efficacy of a cetuximab-based regimen used to treat metastatic colorectal cancer (mCRC) could be influenced by VEGFA polymorphisms. Materials & methods: We studied the effects of five polymorphisms in the VEGFA gene (-2549D/I, -1154G/A, -460T/C, +405G/C and +936C/T) on the outcome of 98 mCRC patients treated with FOLFIRI plus cetuximab. Results: Patients homozygous for the -2549D, -1154G and -460T alleles did exhibit higher response rates to treatment and longer progression-free survival compared with others. In addition, the DGTGC and IGCGC haplotypes were significantly associated with a lower risk of disease progression. Conclusion: These findings suggest that VEGFA genetic variations might influence response/resistance of FOLFIRI plus cetuximab treatment in mCRC patients.
Fichier principal
Vignette du fichier
rollin2015.pdf (190.82 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02381189 , version 1 (12-05-2022)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Jérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, Michelle Boisdron-Celle, Nicolas Azzopardi, et al.. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩. ⟨hal-02381189⟩
77 View
23 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More